ar
Feedback

لا تقع ضحية للمخادعين! تيليمتريو يكتشف ويُميّز هذه القنوات 👉 إذا كنت تريد رؤية العلامة، اشترك

JAMA (Journal of the American Medical Association)

JAMA (Journal of the American Medical Association)

الذهاب إلى القناة على Telegram

All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot

إظهار المزيد

📈 نظرة تحليلية على قناة تيليجرام JAMA (Journal of the American Medical Association)

تُعد قناة JAMA (Journal of the American Medical Association) (@jamaupdates) في القطاع اللغوي الإنكليزية لاعباً نشطاً. يضم المجتمع حالياً 17 069 مشتركاً، محتلاً المرتبة 1 455 في فئة الطب والمرتبة 2 173 في منطقة الولايات المتحدة.

📊 مؤشرات الجمهور والحراك

منذ تأسيسه في невідомо، حقق المشروع نمواً سريعاً وجمع 17 069 مشتركاً.

بحسب آخر البيانات بتاريخ 16 نوفمبر, 2026، تحافظ القناة على نشاط مستقر. خلال آخر 30 يوماً تغيّر عدد الأعضاء بمقدار 371، وفي آخر 24 ساعة بمقدار 13، مع بقاء الوصول العام مرتفعاً.

  • حالة التحقق: غير موثّقة
  • معدل التفاعل (ER): يبلغ متوسط تفاعل الجمهور 4.24‎%. وخلال أول 24 ساعة من النشر يحصد المحتوى عادةً 1.89‎% من ردود الفعل نسبةً إلى إجمالي المشتركين.
  • وصول المنشورات: يحصل كل منشور على متوسط 723 مشاهدة. وخلال اليوم الأول يجمع عادةً 323 مشاهدة.
  • التفاعلات والاستجابة: يتفاعل الجمهور بانتظام؛ متوسط التفاعلات لكل منشور يبلغ 1.
  • الاهتمامات الموضوعية: يركز المحتوى على مواضيع رئيسية مثل patient, disease, treatment, drug, guideline.

📝 الوصف وسياسة المحتوى

يصف المؤلف القناة بأنها مساحة للتعبير عن الآراء الذاتية:
“All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot”

بفضل وتيرة التحديث المرتفعة (أحدث البيانات بتاريخ 17 نوفمبر, 2026) تحافظ القناة على حداثتها ومستوى وصول مرتفع. وتُظهر التحليلات تفاعلاً نشطاً من الجمهور، ما يجعلها نقطة تأثير مهمة ضمن فئة الطب.

17 069
المشتركون
+1324 ساعات
+967 أيام
+37130 أيام
أرشيف المشاركات
Blood Conservation and Choice in Surgical Transfusion https://jamanetwork.com/journals/jama/fullarticle/2856799 This Viewpoint discusses blood conservation and surgical transfusion, including patient blood management and bloodless medicine and surgery, among patients who refuse blood.

Alcohol Consumption During Pregnancy in the US—Reply https://jamanetwork.com/journals/jama/fullarticle/2856800 In Reply We thank Dr Fan and colleagues for their thoughtful letter and for engaging with our study, which reported an increasing trend in alcohol consumption during pregnancy in the US over the past 2 decades. As discussed by the authors, our descriptive results indicate that older maternal age and tobacco use were both notable correlates of any alcohol use, raising questions about overlapping exposure patterns and potential synergistic effects. While our study was designed to assess population-level trends and does not address etiologic aims directly, we are encouraged that the findings have raised other substantive research questions that could have important implications for prevention and practice.

Alcohol Consumption During Pregnancy in the US https://jamanetwork.com/journals/jama/fullarticle/2856801 To the Editor The Research Letter by Dr Bruzelius and colleagues documents increased prevalence of alcohol use among pregnant women in the US from 2011 to 2024, particularly among those with older maternal age (35-49 years; 18.2%) and tobacco use (26.3%). Among pregnant women reporting any alcohol use, 68.1% of those who used tobacco also reported binge or heavy drinking, compared with 31.3% of people who did not use tobacco, suggesting a particularly high-risk subgroup that warrants further investigation.

GLP-1 Utilization After Withdrawal of Medicaid Coverage for Weight Loss https://jamanetwork.com/journals/jama/fullarticle/2856802 This cross-sectional study uses data from Medicaid State Drug Utilization Data to examine associations of coverage withdrawal with Medicaid beneficiaries’ utilization of weight loss–approved glucagon-like peptide-1s.

Absolute Risk of Progression to Cognitive Impairment Based on Plasma p-Tau217, Age, Sex, and APOE ε4 https://jamanetwork.com/journals/jamaneurology/fullarticle/2856722 This cohort study examines data from the Mayo Clinic Study of Aging and Alzheimer’s Disease Neuroimaging Initiative to determine the 5- and 10-year absolute risks of mild cognitive impairment and dementia among individuals who are biomarker positive and cognitively unimpaired.

Agent Orange Exposure and Parkinson Disease Among US Veterans https://jamanetwork.com/journals/jamaneurology/fullarticle/2856723 This cohort study investigates the association between Agent Orange and risk of incident Parkinson disease diagnosis among US veterans.

Nationwide Geographic Access to Subcutaneous Anti-Amyloid Alzheimer Disease Therapy Infrastructure https://jamanetwork.com/journals/jamaneurology/fullarticle/2856724 This cross-sectional study describes how geographic availability of the minimum health care infrastructure required for subcutaneous therapy for Alzheimer disease treatment varies by age and location across the US.

Intraocular Hemorrhage After Digital Subtraction Myelography https://jamanetwork.com/journals/jamaneurology/fullarticle/2856725 This case report describes a young adult patient with intraretinal hemorrhages in both eyes resulting in reduction of visual acuity in the left eye.

Agent Orange and Parkinson Disease—The War Ended, the Exposure Did Not https://jamanetwork.com/journals/jamaneurology/fullarticle/2856726 Agent Orange was a defoliant widely used by the US during the Vietnam War to uncover the positions of North Vietnamese soldiers. The weed killer was a 50:50 mixture of the herbicides 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) along with small amounts of a potent carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a by-product of the manufacturing process. From 1962 to 1971, the US sprayed at least 75 million liters (20 million gallons) of defoliants over Vietnam and more over Cambodia, Laos, Thailand, South Korea, and possibly Guam, Panama, and even around military bases in the US.

HEPA Filtration in Care Homes—Distinguishing Implementation From Intervention Failure https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856318 To the Editor Hay et al should be commended for conducting one of the first large pragmatic trials addressing an important and clinically relevant infection-prevention strategy in a highly vulnerable population. However, I believe that several aspects of this study warrant further consideration.

Evaluation of Identified Serious Risks for Drugs and Biologics Using Surveillance Systems https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856319 This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.

Value Judgments in Comparing Dialysis Facility Performance https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856321 In 2025, the Centers for Medicare & Medicaid Services (CMS) stopped collecting information about race and ethnicity in the dialysis quality measurement system. Koukounas and colleagues in this issue of JAMA Internal Medicine consider how this change might impact comparisons among dialysis facilities. Using national data, they estimated standardized mortality ratios (SMRs) for these facilities, contrasting the results from risk-adjustment models that either include or exclude race and ethnicity. They find that dialysis facilities that serve more socially disadvantaged patients have better SMRs when the model does not adjust for race and ethnicity.

Pediatric Obesity Pharmacotherapy https://jamanetwork.com/journals/jama/fullarticle/2856798 In the current issue of JAMA, Dr Kelly and colleagues present results from SURMOUNT-ADOLESCENTS, a clinical trial of tirzepatide among adolescents with obesity. The results are impressive: mean body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) decreased by 18.5% with tirzepatide compared with a 0.5% increase with placebo, a treatment difference of 19 percentage points at 72 weeks. Nearly half of tirzepatide-treated participants achieved a BMI reduction of at least 20%, and 53.5% of tirzepatide-treated participants achieved a BMI below the 95th percentile at week 72, compared with 7.1% receiving placebo. As evidence supporting antiobesity medications continues to mount, the question is increasingly not whether pharmacotherapy has a role in pediatric obesity treatment, but which medications should be used for which patients and under what circumstances.

FDA Approves Novel Treatment for Chronic Hepatitis B https://jamanetwork.com/journals/jama/fullarticle/2856883 The US Food and Drug Administration (FDA) approved bepirovirsen, marketed as Hibsago, in combination with existing antiviral therapy for adults without cirrhosis who have chronic hepatitis B virus (HBV) infection.

Updated Guidance Released for Type 2 Diabetes Care https://jamanetwork.com/journals/jama/fullarticle/2856884 The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) released a joint consensus statement offering updated clinical guidance for type 2 diabetes.

Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence Risk https://jamanetwork.com/journals/jama/fullarticle/2856885 A personalized messenger RNA (mRNA) cancer vaccine significantly lowered the risk of disease recurrence or death in patients with high-risk melanoma, a phase 3 trial found.

Why Do COVID-19 Shots Trigger a Fever for Some? https://jamanetwork.com/journals/jama/fullarticle/2856877 This Medical News article discusses a study that linked the gut microbiome to fever after COVID-19 vaccination.

Salt Substitutes Come to the Table https://jamanetwork.com/journals/jama/fullarticle/2856876 This Medical News article discusses efforts to increase the use of potassium-enriched salt substitutes to lower sodium intake and prevent and manage hypertension.

JAMA Editors' Summary Podcast November 13, 2026 https://jamanetwork.com/journals/jama/fullarticle/2856887 Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.

US Health Insurance Coverage Declines https://jamanetwork.com/journals/jama/fullarticle/2856886 US health insurance coverage and access are in decline after 15 years of expansion, according to a 2026 survey from the Commonwealth Fund.